Chan Henry Lee Sells 700 Shares of Beigene, Ltd. (NASDAQ:ONC) Stock

Beigene, Ltd. (NASDAQ:ONC) SVP Chan Henry Lee sold 700 shares of the firm’s stock in a transaction on Friday, June 6th. The shares were sold at an average price of $256.11, for a total value of $179,277.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Beigene Price Performance

Beigene stock opened at $276.53 on Friday. The stock has a 50 day moving average price of $240.18. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. Beigene, Ltd. has a fifty-two week low of $141.31 and a fifty-two week high of $287.88. The stock has a market capitalization of $32.74 billion, a P/E ratio of -33.56, a P/E/G ratio of 7.73 and a beta of 0.30.

Beigene (NASDAQ:ONC) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $1.93. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. On average, analysts expect that Beigene, Ltd. will post -5.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ONC. TD Securities reaffirmed a “buy” rating and issued a $334.00 price target on shares of Beigene in a research note on Thursday, April 24th. Wall Street Zen raised Beigene from a “hold” rating to a “buy” rating in a report on Thursday, May 22nd. JPMorgan Chase & Co. upped their target price on Beigene from $311.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday, April 21st. Sanford C. Bernstein set a $259.00 price target on Beigene in a research report on Thursday, March 13th. Finally, Royal Bank of Canada lowered their price objective on shares of Beigene from $312.00 to $311.00 and set an “outperform” rating on the stock in a research note on Thursday, May 8th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $319.00.

About Beigene

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.